Early research suggests a blood score combining vitamin B12 and C-reactive protein may help estimate outlook in advanced cancer. A 2026 case report calculated a score of 18,917 for one patient. According to research reviewed by Gram, this single-patient finding needs larger studies before doctors can rely on it.

Doctors need simple tests that can help predict how advanced cancer may progress. A new case report, published in the Journal of Medical Cases in 2026, looked at a blood measure that combines vitamin B12 and inflammation. The researchers studied one 64-year-old man with advanced bile duct cancer that had spread to the liver, lungs, and abdominal lining despite chemotherapy and immunotherapy. His vitamin B12 level was very high, and his inflammation marker, C-reactive protein, was elevated. Combining these two numbers produced a score the authors call the B12-CRP index, which was 18,917. The authors suggest this score could become a useful extra tool for planning palliative care, which focuses on comfort and quality of life. According to research reviewed by Gram, the findings are preliminary because they come from a single patient, and larger studies are needed before doctors rely on this measure.

Key Statistics

A 2026 case report published in the Journal of Medical Cases described one 64-year-old man with advanced bile duct cancer whose B12-CRP index was 18,917.

In the reported patient, vitamin B12 measured 1,126 pmol/L and C-reactive protein measured 16.8 mg/L, while his Palliative Performance Scale score was 50 percent.

The 2026 case report noted that the patient’s cancer progressed five months after diagnosis despite treatment with gemcitabine, cisplatin, and durvalumab.

The Quick Take

  • What they studied: Can a simple blood score that combines vitamin B12 and inflammation help doctors estimate how well a person with advanced cancer may do?
  • Who participated: One man, age 64, with a rare and aggressive bile duct cancer. He had been diagnosed 5 months earlier and had received chemotherapy and an immunotherapy drug, but his cancer had grown and spread.
  • Key finding: The man’s vitamin B12 level was 1,126 pmol/L, far above the normal range, and his inflammation marker was 16.8 mg/L. Multiplying these numbers gave a score of 18,917. Because this is one patient, the score cannot yet show whether it reliably predicts outcomes for others.
  • What it means for you: This is an early idea, not a test you can act on today. If you or a loved one has advanced cancer, talk with your care team about your prognosis and about palliative care options. Do not change any treatment based on this report.

The Research Details

This report describes the medical history, scans, and lab results of one patient with advanced cancer. The care team reviewed his symptoms, imaging tests, and blood work to understand how his disease was changing and how well he was able to take care of himself.

The authors then calculated a simple score called the B12-CRP index. They multiplied the vitamin B12 level, measured in picomoles per liter, by the C-reactive protein level, measured in milligrams per liter. C-reactive protein is a general marker that rises when the body has inflammation, which can happen when cancer is active.

The authors also summarized earlier published studies on high vitamin B12, inflammation, and cancer outcomes. This summary was narrative, meaning it was a written overview rather than a formal statistical pooling of results.

A case report is a good way to notice an unusual pattern and describe it carefully. It can point researchers toward ideas worth testing. However, one patient cannot show that a pattern is common or that a test works for most people. The authors appear to be using this case as a starting point for future research.

The report gives a clear, detailed account of one patient, including scan findings, symptom scores, and lab values, and the math behind the score is simple and transparent. However, it includes only one person, so it cannot show cause and effect or how accurate the score is. The authors say prospective studies, which follow many patients over time, are still needed. The journal’s reputation and impact factor are not confirmed in the information provided, so readers should weigh the findings with caution.

What the Results Show

The patient’s cancer had grown significantly after five months of treatment with gemcitabine, cisplatin, and durvalumab. Scans showed spread to the liver, blockage of a major vein that carries blood to the liver, cancer spread across the lining of the abdomen, and small spots in the lungs.

His vitamin B12 level was 1,126 pmol/L. Doctors consider vitamin B12 high when it goes above the typical reference range, and levels this high are often seen in people with certain cancers or liver problems. His C-reactive protein was 16.8 mg/L, which points to ongoing inflammation in the body.

When these two numbers were multiplied, the result was 18,917. The authors used this score as a way to summarize how high vitamin B12 and inflammation were occurring together. Because there is no comparison group or earlier score to measure against, the number cannot yet be interpreted as a clear warning level.

His overall condition had also declined sharply. His Palliative Performance Scale score was 50 percent, a measure of how much a person can still do on their own, which indicates he needed substantial help with daily activities. Blood tests also showed low albumin, a protein that helps keep fluid in the bloodstream, along with liver stress and high calcium. Given his situation, palliative care was recommended.

The patient also had low albumin, which is often linked to poorer nutrition and more inflammation in people with cancer. Liver blood tests showed bile flow problems and liver cell stress, consistent with the spread of his cancer to the liver. High calcium can also occur with advanced cancer and can cause confusion, weakness, and other symptoms.

These additional results matter because doctors already watch albumin, liver tests, and calcium when judging how sick a patient is. The authors suggest the B12-CRP index might be added to this group of measures, but the case alone cannot show whether it adds useful information.

The authors point to earlier research linking high vitamin B12 with inflammation and with worse outcomes in some cancers. Doctors already use inflammation markers such as C-reactive protein and albumin to help estimate prognosis in advanced cancer. The B12-CRP index is an attempt to combine these ideas into one number. Its value will depend on future studies that compare it directly with existing tools.

The biggest limitation is that the report covers only one patient. A single case cannot show whether the B12-CRP index predicts survival or treatment response for other people. Vitamin B12 and inflammation can also rise for many reasons, including liver disease, infections, and other medical conditions, which were not ruled out as explanations in a way that would prove the score is specific to cancer. The score also has no established cutoff values, so no one can yet say what number is high enough to matter. Finally, the authors themselves note that prospective studies are needed before the index can guide decisions in palliative medicine.

The Bottom Line

Based on this single case report, the B12-CRP index should be viewed as a promising idea rather than an established medical tool. Confidence in its usefulness is low at this stage. Doctors and researchers would need studies with many patients, ideally comparing the score with survival and with existing prognostic measures, before recommending it in routine care. Patients should continue to follow the advice of their own medical team.

Oncologists, palliative care teams, and researchers studying prognosis in advanced cancer may find this idea worth following. Patients and families dealing with advanced cancer may be interested in new tools, but should not expect this score to be available or meaningful yet. People without cancer, or with early-stage disease, should not use this report to make health decisions.

Any real-world use of the B12-CRP index is likely years away. It would first need to be tested in larger studies, then validated in different cancer types and patient groups, and finally adopted into clinical guidelines. Patients should not expect any change in their care based on this report alone.

Frequently Asked Questions

What is the B12-CRP index in cancer research?

The B12-CRP index is a score calculated by multiplying vitamin B12 in pmol/L by C-reactive protein in mg/L. A 2026 case report proposed it as a possible extra tool for estimating prognosis in advanced cancer, but it has only been tested in one patient so far.

Can vitamin B12 levels predict how advanced cancer will progress?

Research on this question is still very early. A 2026 case report suggests high vitamin B12 combined with inflammation may signal poorer outlook, but this came from a single patient. Larger studies are needed before vitamin B12 can be used to predict cancer progression reliably.

What does C-reactive protein tell doctors about cancer?

C-reactive protein is a blood marker that rises when the body is inflamed. In advanced cancer, higher levels can reflect active disease. A 2026 case report measured 16.8 mg/L in one patient with spreading cholangiocarcinoma, but a single value cannot diagnose or predict outcomes on its own.

Should I ask my doctor about the B12-CRP index?

You can ask your doctor about any prognostic tools they use, but the B12-CRP index is not yet a standard test. It was proposed in a 2026 case report involving one patient. Your care team can explain which blood tests are most useful for your situation and what they mean.

Want to Apply This Research?

  • Users who have been given blood test results by their doctor can record their vitamin B12 and C-reactive protein values, along with the date and lab reference ranges, in the app. The app can then calculate the product of the two values, which is the same method the authors used, and display it alongside the date. Users should label this as a personal record and not a diagnostic score.
  • Encourage users to bring a written list of their latest test results, symptoms, and daily functioning to each medical appointment. Prompt them to ask their care team which measures they use to estimate prognosis and whether palliative care support is available. Remind users never to change or stop prescribed treatment based on app-calculated numbers.
  • Over the long term, users can log lab results at each doctor visit, along with a simple daily function rating, such as how many daily activities they can complete independently. Reviewing trends over months, rather than single values, can help users and their care teams talk about changes. The app should remind users that trends must be interpreted by a medical professional.

This article summarizes a single case report and is for general educational purposes only. It is not medical advice and should not be used to diagnose, treat, or make decisions about cancer care. The B12-CRP index has not been validated in larger studies. Anyone with advanced cancer or concerns about their prognosis should speak with their oncology or palliative care team.

This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.

Source: The Vitamin B12-C-Reactive Protein Index in Advanced Cancer: A Case Report and Narrative Review of an Underutilized Potential Prognostic Biomarker. , Journal of medical cases (2026). PubMed 43042426 | DOI
Topics
vitamin B12 C-reactive protein advanced cancer palliative care prognostic biomarker cholangiocarcinoma inflammation markers case report